Post-Authorization Activity Table (PAAT) for Pomalyst

This PAAT describes post-authorization activity for Pomalyst, a product which contains the medicinal ingredient pomalidomide. Based on Health Canada's review, the benefit/risk profile of Pomalyst is considered favourable, in combination with dexamethasone (Pomalyst+LD-dex), for patients with multiple myeloma (MM) for whom both bortezomib and lenalidomide have failed and who have received at least two prior treatment regimens and have demonstrated disease progression on the last regimen. Read more here.